Literature DB >> 26169272

Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains.

Raul Herrera1, Charles Anderson1, Krishan Kumar1, Alvaro Molina-Cruz2, Vu Nguyen1, Martin Burkhardt1, Karine Reiter1, Richard Shimp1, Randall F Howard3, Prakash Srinivasan2, Michael J Nold4, Daniel Ragheb5, Lirong Shi5, Mark DeCotiis1, Joan Aebig1, Lynn Lambert1, Kelly M Rausch1, Olga Muratova1, Albert Jin6, Steven G Reed3, Photini Sinnis5, Carolina Barillas-Mury2, Patrick E Duffy1, Nicholas J MacDonald1, David L Narum7.   

Abstract

The extended rod-like Plasmodium falciparum circumsporozoite protein (CSP) is comprised of three primary domains: a charged N terminus that binds heparan sulfate proteoglycans, a central NANP repeat domain, and a C terminus containing a thrombospondin-like type I repeat (TSR) domain. Only the last two domains are incorporated in RTS,S, the leading malaria vaccine in phase 3 trials that, to date, protects about 50% of vaccinated children against clinical disease. A seroepidemiological study indicated that the N-terminal domain might improve the efficacy of a new CSP vaccine. Using a panel of CSP-specific monoclonal antibodies, well-characterized recombinant CSPs, label-free quantitative proteomics, and in vitro inhibition of sporozoite invasion, we show that native CSP is N-terminally processed in the mosquito host and undergoes a reversible conformational change to mask some epitopes in the N- and C-terminal domains until the sporozoite interacts with the liver hepatocyte. Our findings show the importance of understanding processing and the biophysical change in conformation, possibly due to a mechanical or molecular signal, and may aid in the development of a new CSP vaccine.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26169272      PMCID: PMC4567636          DOI: 10.1128/IAI.02676-14

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

Authors:  Selidji Todagbe Agnandji; Bertrand Lell; Solange Solmeheim Soulanoudjingar; José Francisco Fernandes; Béatrice Peggy Abossolo; Cornelia Conzelmann; Barbara Gaelle Nfono Ondo Methogo; Yannick Doucka; Arnaud Flamen; Benjamin Mordmüller; Saadou Issifou; Peter Gottfried Kremsner; Jahit Sacarlal; Pedro Aide; Miguel Lanaspa; John J Aponte; Arlindo Nhamuave; Diana Quelhas; Quique Bassat; Sofia Mandjate; Eusébio Macete; Pedro Alonso; Salim Abdulla; Nahya Salim; Omar Juma; Mwanajaa Shomari; Kafuruki Shubis; Francisca Machera; Ali Said Hamad; Rose Minja; Ali Mtoro; Alma Sykes; Saumu Ahmed; Alwisa Martin Urassa; Ali Mohammed Ali; Grace Mwangoka; Marcel Tanner; Halidou Tinto; Umberto D'Alessandro; Hermann Sorgho; Innocent Valea; Marc Christian Tahita; William Kaboré; Sayouba Ouédraogo; Yara Sandrine; Robert Tinga Guiguemdé; Jean Bosco Ouédraogo; Mary J Hamel; Simon Kariuki; Chris Odero; Martina Oneko; Kephas Otieno; Norbert Awino; Jackton Omoto; John Williamson; Vincent Muturi-Kioi; Kayla F Laserson; Laurence Slutsker; Walter Otieno; Lucas Otieno; Otsyula Nekoye; Stacey Gondi; Allan Otieno; Bernhards Ogutu; Ruth Wasuna; Victorine Owira; David Jones; Agnes Akoth Onyango; Patricia Njuguna; Roma Chilengi; Pauline Akoo; Christine Kerubo; Jesse Gitaka; Charity Maingi; Trudie Lang; Ally Olotu; Benjamin Tsofa; Philip Bejon; Norbert Peshu; Kevin Marsh; Seth Owusu-Agyei; Kwaku Poku Asante; Kingsley Osei-Kwakye; Owusu Boahen; Samuel Ayamba; Kingsley Kayan; Ruth Owusu-Ofori; David Dosoo; Isaac Asante; George Adjei; George Adjei; Daniel Chandramohan; Brian Greenwood; John Lusingu; Samwel Gesase; Anangisye Malabeja; Omari Abdul; Hassan Kilavo; Coline Mahende; Edwin Liheluka; Martha Lemnge; Thor Theander; Chris Drakeley; Daniel Ansong; Tsiri Agbenyega; Samuel Adjei; Harry Owusu Boateng; Theresa Rettig; John Bawa; Justice Sylverken; David Sambian; Alex Agyekum; Larko Owusu; Francis Martinson; Irving Hoffman; Tisungane Mvalo; Portia Kamthunzi; Ruthendo Nkomo; Albans Msika; Allan Jumbe; Nelecy Chome; Dalitso Nyakuipa; Joseph Chintedza; W Ripley Ballou; Myriam Bruls; Joe Cohen; Yolanda Guerra; Erik Jongert; Didier Lapierre; Amanda Leach; Marc Lievens; Opokua Ofori-Anyinam; Johan Vekemans; Terrell Carter; Didier Leboulleux; Christian Loucq; Afiya Radford; Barbara Savarese; David Schellenberg; Marla Sillman; Preeti Vansadia
Journal:  N Engl J Med       Date:  2011-10-18       Impact factor: 91.245

2.  Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.

Authors:  Kazutoyo Miura; Andrew C Orcutt; Olga V Muratova; Louis H Miller; Allan Saul; Carole A Long
Journal:  Vaccine       Date:  2007-11-20       Impact factor: 3.641

Review 3.  Apical membrane antigen 1: a malaria vaccine candidate in review.

Authors:  Edmond J Remarque; Bart W Faber; Clemens H M Kocken; Alan W Thomas
Journal:  Trends Parasitol       Date:  2008-01-15

4.  Antimalarial activity of allicin, a biologically active compound from garlic cloves.

Authors:  Alida Coppi; Melissa Cabinian; David Mirelman; Photini Sinnis
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice.

Authors:  Kathrin Kastenmüller; Diego A Espinosa; Lauren Trager; Cristina Stoyanov; Andres M Salazar; Santosh Pokalwar; Sanjay Singh; Sheetij Dutta; Christian F Ockenhouse; Fidel Zavala; Robert A Seder
Journal:  Infect Immun       Date:  2012-12-28       Impact factor: 3.441

6.  Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.

Authors:  Joanne M Lumsden; Sathit Pichyangkul; Utaiwan Srichairatanakul; Kosol Yongvanitchit; Amporn Limsalakpetch; Saule Nurmukhambetova; Jennifer Klein; Sylvie Bertholet; Thomas S Vedvick; Steven G Reed; Jetsumon Sattabongkot; Jason W Bennett; Mark E Polhemus; Christian F Ockenhouse; Randall F Howard; Anjali Yadava
Journal:  Infect Immun       Date:  2011-06-20       Impact factor: 3.441

7.  The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.

Authors:  Silayuv E Bongfen; Patricia M Ntsama; Sandra Offner; Thomas Smith; Ingrid Felger; Marcel Tanner; Pedro Alonso; Issa Nebie; Jackeline F Romero; Olivier Silvie; Ralph Torgler; Giampietro Corradin
Journal:  Vaccine       Date:  2008-11-05       Impact factor: 3.641

8.  Heparan sulfate proteoglycans provide a signal to Plasmodium sporozoites to stop migrating and productively invade host cells.

Authors:  Alida Coppi; Rita Tewari; Joseph R Bishop; Brandy L Bennett; Roger Lawrence; Jeffrey D Esko; Oliver Billker; Photini Sinnis
Journal:  Cell Host Microbe       Date:  2007-11-15       Impact factor: 21.023

9.  Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate.

Authors:  Matthew L Plassmeyer; Karine Reiter; Richard L Shimp; Svetlana Kotova; Paul D Smith; Darrell E Hurt; Brent House; Xiaoyan Zou; Yanling Zhang; Merrit Hickman; Onyinyechukwu Uchime; Raul Herrera; Vu Nguyen; Jacqueline Glen; Jacob Lebowitz; Albert J Jin; Louis H Miller; Nicholas J MacDonald; Yimin Wu; David L Narum
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

10.  The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host.

Authors:  Alida Coppi; Ramya Natarajan; Gabriele Pradel; Brandy L Bennett; Eric R James; Mario A Roggero; Giampietro Corradin; Cathrine Persson; Rita Tewari; Photini Sinnis
Journal:  J Exp Med       Date:  2011-01-24       Impact factor: 14.307

View more
  26 in total

1.  Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.

Authors:  Nicholas J MacDonald; Vu Nguyen; Richard Shimp; Karine Reiter; Raul Herrera; Martin Burkhardt; Olga Muratova; Krishan Kumar; Joan Aebig; Kelly Rausch; Lynn Lambert; Nikiah Dawson; Jetsumon Sattabongkot; Xavier Ambroggio; Patrick E Duffy; Yimin Wu; David L Narum
Journal:  J Biol Chem       Date:  2016-07-18       Impact factor: 5.157

Review 2.  Malaria vaccines since 2000: progress, priorities, products.

Authors:  Patrick E Duffy; J Patrick Gorres
Journal:  NPJ Vaccines       Date:  2020-06-09       Impact factor: 7.344

3.  Force Spectroscopy of the Plasmodium falciparum Vaccine Candidate Circumsporozoite Protein Suggests a Mechanically Pliable Repeat Region.

Authors:  Aditya Prasad Patra; Shobhona Sharma; Sri Rama Koti Ainavarapu
Journal:  J Biol Chem       Date:  2016-12-27       Impact factor: 5.157

4.  VAR2CSA Domain-Specific Analysis of Naturally Acquired Functional Antibodies to Plasmodium falciparum Placental Malaria.

Authors:  Justin Yai Alamou Doritchamou; Raul Herrera; Joan A Aebig; Robert Morrison; Vu Nguyen; Karine Reiter; Richard L Shimp; Nicholas J MacDonald; David L Narum; Michal Fried; Patrick E Duffy
Journal:  J Infect Dis       Date:  2016-05-18       Impact factor: 5.226

Review 5.  Repetitive sequences in malaria parasite proteins.

Authors:  Heledd M Davies; Stephanie D Nofal; Emilia J McLaughlin; Andrew R Osborne
Journal:  FEMS Microbiol Rev       Date:  2017-11-01       Impact factor: 16.408

6.  The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable.

Authors:  Susheel K Singh; Jordan Plieskatt; Bishwanath Kumar Chourasia; Vandana Singh; Judith M Bolscher; Koen J Dechering; Bright Adu; Blanca López-Méndez; Swarnendu Kaviraj; Emily Locke; C Richter King; Michael Theisen
Journal:  J Biol Chem       Date:  2019-12-02       Impact factor: 5.157

Review 7.  Antibodies against Plasmodium falciparum malaria at the molecular level.

Authors:  Jean-Philippe Julien; Hedda Wardemann
Journal:  Nat Rev Immunol       Date:  2019-08-28       Impact factor: 53.106

Review 8.  Thrombospondin Related Anonymous Protein Superfamily in Vector-Borne Apicomplexans: The Parasite's Toolkit for Cell Invasion.

Authors:  Martina Soledad Paoletta; Silvina Elizabeth Wilkowsky
Journal:  Front Cell Infect Microbiol       Date:  2022-04-06       Impact factor: 6.073

9.  Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.

Authors:  Kawsar R Talaat; Ruth D Ellis; Janet Hurd; Autumn Hentrich; Erin Gabriel; Noreen A Hynes; Kelly M Rausch; Daming Zhu; Olga Muratova; Raul Herrera; Charles Anderson; David Jones; Joan Aebig; Sarah Brockley; Nicholas J MacDonald; Xiaowei Wang; Michael P Fay; Sara A Healy; Anna P Durbin; David L Narum; Yimin Wu; Patrick E Duffy
Journal:  PLoS One       Date:  2016-10-17       Impact factor: 3.240

10.  A Method for Producing Protein Nanoparticles with Applications in Vaccines.

Authors:  David S Jones; Christopher G Rowe; Beth Chen; Karine Reiter; Kelly M Rausch; David L Narum; Yimin Wu; Patrick E Duffy
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.